- Details
- In this discussion, Zach Klaassen and Sarah Psutka focus on muscle-invasive bladder cancer and the challenges faced by high-risk patients undergoing radical cystectomy. They discuss the complexities of the surgery, including the reconstructive and bowel components, as well as the comorbidities and frailty commonly observed in bladder cancer patients. The importance of evaluating social support and...
|
- Details
- In this conversation, Ashish Kamat welcomes Andrea Necchi to present his research on the Vesical Imaging-Reporting and Data System (VI-RADS) and its correlation with the pathologic and molecular outcomes of patients undergoing perioperative IO therapy in the context of the PURE-01 study. The study focuses on the evaluation of MRI data and the response to neoadjuvant Pembrolizumab in muscle-invasiv...
|
- Details
- In this conversation hosted by Ashish Kamat, Professors Param Mariappan and Maria Carmen Mir debate the pros and cons of organ-sparing cystectomy in bladder cancer patients. Professor Param Mariappan opposed the motion of organ preservation, highlighting the challenges and complexities associated with preserving reproductive organs for continence and sexual function. He discussed the limitations o...
|
- Details
- Matt Galsky joins Sam Chang in a conversation about the long-term results of the IMvigor130 randomized phase III study which evaluated the use of atezolizumab in combination with platinum/gemcitabine chemotherapy versus platinum/gemcitabine chemotherapy alone in patients with metastatic urothelial carcinoma. The study used a hierarchical statistical analysis plan, and the first analysis showed a s...
|
- Details
- Jason Brown joins Sam Chang in conversation on the results of neoadjuvant combination therapy prior to cystectomy and nephroureterectomy. This is a multi-institutional phase Ib/II two-stage study investigating chemo-immunotherapy in patients with cisplatin-eligible or ineligible muscle-invasive urothelial carcinoma. The treatment for cisplatin-eligible patients included gemcitabine, cisplatin, and...
|
- Details
- Matthew Galsky and Alicia Morgans discuss the co-primary endpoint analysis of HCRN GU 16-257, a phase II clinical trial investigating the efficacy of gemcitabine, cisplatin, and nivolumab in patients with muscle-invasive bladder cancer who are undergoing selective bladder-sparing treatment. The trial investigated whether a subset of patients could be treated with systemic therapy and avoid definit...
|
- Details
- Tanya Jindal and Vadim Koshkin join Petros Grivas to discuss their work to help identify potential biomarkers of response to enfortumab vedotin (EV) in patients with advanced urothelial carcinoma using a patient cohort in the UNITE dataset. The UNITE study researchers analyzed biomarkers associated with enfortumab vedotin (EV) treatment outcomes in patients with advanced urothelial carcinoma. They...
|
- Details
- Matthew Milowsky joins Sam Chang in a discussion on the patient-reported outcomes from Cohort K of the EV-103 Phase 1b/2 study which analyzed the impact of enfortumab vedotin (EV) alone or combined with pembrolizumab on patients with locally advanced or metastatic urothelial carcinoma who were ineligible for cisplatin. The objective was to describe the impact on the patients' quality of life (QoL)...
|
- Details
- Michiel Van der Heijden joins Alicia Morgans to discuss the NABUCCO trial, which investigated preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer. The study enrolled patients with Stage 3 disease, including both cisplatin-ineligible and cisplatin-refusing patients, with about 40% being node-positive. In cohort 1, high pathological complete response rates were observ...
|
- Details
- Matt Galsky joins Sam Chang in a conversation about the long-term results of CheckMate 274, a randomized phase III study that enrolled patients with muscle-invasive urothelial cancer at high risk for recurrence after radical surgery. Patients were randomized to receive adjuvant nivolumab or placebo, with adjuvant nivolumab given for up to a year. The study's co-primary endpoints were disease-free...
|
